EuroPCR 2024: Late-Breaking Science Video Collection
Published: 20 May 2024
-
Views:
1178
-
Likes:
7
-
Views:
1178
-
Likes:
7
-
Up Next -
3m 44sPart 1 | Session 2 Influence of Pathophysiological Patterns of CAD on PCI -
5m 19sPart 1 | Session 3 Ancillary SMART Trial Analyses -
3m 59sPart 1 | Session 4 Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY -
4m 6s -
26m 48sPart 1 | Session 6 1M DAPT Followed by 5M Ticagrelor Monotherapy in ACS with DCB: CAGEFREE II
-
26m 3sPart 2 | Session 1 View from the Thoraxcenter: What's Hot at EuroPCR 24? -
18m 29sPart 2 | Session 2 View from the Thoraxcenter: EuroPCR 24 Wrap Up - Part 1
-
4m 13sPart 3 | Session 1 5 Trials That Will Change My Practice With Dr Mirvat Alasnag -
6m 27sPart 3 | Session 2 4 Trials That Will Change My Practice with Dr Bernardo Cortese
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2024 from selected faculty in our Highlights Reviews.
More from this programme
Part 1
Expert Interviews
Part 2
View from the Thoraxcenter
Part 3
Highlights Reviews
About the episode
EuroPCR 24 - In this succinct interview, we are joined by Dr Hans-Josef Feistritzer (University of Leipzig, DE) to discuss the findings of the SOLVE-TAVI Trial.
In recent years, trials such as CHOICE, REPRISE III, the SCOPE trial, PORTICO IDE and the SMART trial have privided increasing evidence for direct TACI valve comparisons as device designs improve. TAVI is increasingly performed using local anaesthesia and conscious sedation, or local anaesthesia only.
The SOLVE-TAVI trial used a 2x2 factorial design to compare both valve strategies (CoreValve Evolut R or Edwards Sapien 3) and anaesthesia strategies (conscious sedation and general anaesthesia) in a group of 447 patients with symptomatic aortic stenosis and an indication for TAVR.
Findings showed similar outcomes in both valve groups at 5 years, though stroke rate was higher in the Sapien 3 group. In terms of anaesthesia strategy, conscious sedation and general anaesthesia both resulted in similar outcomes in regard to the composite primary endpoint at 5 years, though mortality was lower in the conscious sedation group.
Interview Questions:
- What is the importance of SOLVE-TAVI?
- What was the study design, eligibility criteria and outcome measures?
- What are the findings presented at EuroPCR 24?
- What are the take-home messages for practice?
- What are the next steps?
Recorded onsite at EuroPCR 2024, Paris
Comments